Difference between revisions of "Transcription factor p65"
m |
m |
||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 50: | Line 50: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase interaction partners|*]] | [[Category:Tissue transglutaminase interaction partners|*]] | ||
Latest revision as of 12:25, 10 March 2015
| Transcription factor p65 | |
|---|---|
| Substrate peptide name | Transcription factor p65 |
| Synonyms | Nuclear factor NF-kappa-B p65 subunit |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cytosol/Nucleus |
| Swissprot ID | Q04206 |
| Interacting residues | |
| Interacting sequence | |
| TG2 Swissprot ID | P21980 |
| Interacting residues of TG2 | |
| Interacting sequence of TG2 | |
| Structure | 1NFI |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:14755292 |
| Notes | |
